Some Wall Street analysts are wary of Boston Scientific’s decision to hold back some of the safety results from a trial of its Watchman stroke prevention implant.
Officials at Boston Scientific (NYSE:BSX) announced this week that they would reveal only limited patient safety results when they present data from a clinical trial of the Watchman stroke prevention implant at the American College of Cardiology conference this week.
The Massachusetts-based medical device giant revealed in a press release that it plans to “present the acute procedural safety results of the PREVAIL clinical trial,” keeping 2 other safety endpoints under wraps for the time being.